Compare Geo Group Inc (The) REIT (GEO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Geo Group Inc (The) REIT vs Tango Therapeutics Inc. — how do they compare? Geo Group Inc (The) REIT trades at $30.87 (market cap $4.24B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Geo Group Inc (The) REIT and Tango Therapeutics Inc. are close in size by market cap, and Geo Group Inc (The) REIT is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Geo Group Inc (The) REIT for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| GEO | TNGX | |
|---|---|---|
Market Cap | $4.24B | $3.75B |
Volume | 1,580,830 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $32.77 | $32.90 |
52-Week Low | $13.26 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.79B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GEO trades at $32.19, up 1.45% today, with a bullish technical signal from moving averages. Recent earnings beats in Q1 and Q2 2026, alongside a net income margin of 10.31% and ROE of 20.11%, highlight strong profitability. The company recently sold its Adelanto facilities for $950 million and increased its share repurchase authorization to $1.25 billion, signaling financial strength and shareholder returns.
The outlook is positive, supported by analyst consensus (66.7% buy ratings) and recent Zacks upgrades to Strong Buy. Key opportunities include earnings momentum and strategic asset sales, while risks involve debt management and potential regulatory scrutiny. The stock's valuation, with a P/E of 15.18, appears reasonable given growth prospects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Geo Group Inc (The) REIT
The GEO Group provides correctional, detention, and community reentry services. Its operations include secure facilities, electronic monitoring, and support programs for individuals in the criminal-justice system.
Read more on GEO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
